Montara Therapeutics, a biotech company pioneering brain-selective therapies for central nervous system (CNS) diseases, today announced it has received a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF), in addition to joining MJFF’s LRRK2 Investigative Therapeutics Exchange (LITE) program, which supports the development of new therapies that target LRRK2 while also advancing progress toward new LRRK2-relevant clinical biomarkers.
Innovation Ventures salutes UCSF principal investigator Kevan Shokat for the success of his technology.